MATTAWAN, MICH., December 19 /CNW/ - MPI Research and Shanghai Medicilon
are pleased to announce a new joint venture to form Medicilon-MPI Preclinical
Research (Shanghai) LLC. Located initially at the Zhangjiang Hi-Tech Park in
Shanghai, China, the company will open a 50,000 ft(2) preclinical testing
facility in the Chuansha Economic Park in early 2008. This new facility will
meet the regulatory standards set forth by the US FDA and other regulatory
With the joint venture, customers of both parent companies will have the
advantage of conducting research at the Shanghai site for preclinical
development, with potential for worldwide release. Current and future
customers of Medicilon and MPI Research will now have access to a broader
range of both GLP and non-GLP preclinical services. By 2009, the new company
will be fully operational, in terms of conducting FDA/IND enabling studies,
offering additional preclinical support services, submitting INDs and NDAs,
and will have AAALAC accreditation.
"With one fourth of the world's population, China is an important force
in shaping the global pharmaceutical and biotechnology markets," says MPI
Research's Chairman and CEO, William U. Parfet. "We have carefully looked for
more than three years to find a CRO partner that shares our values and
commitment to excellence, and we have finally found one in Shanghai Medicilon.
We look forward to forging a future together as a worldwide leader of
preclinical research services."
Dr. Chun-Lin Chen, co-founder of Medicilon, Inc. as well as Shanghai
Medicilon will serve as the CEO of Medicilon-MPI Preclinical Research. Dr Chen
is a highly published thoughtleader in the pharmaceutical industry with
extensive experience in academia, pharmaceutical, and regulatory evaluation.
Dr. Chen received his PhD from Oklahoma State University, and completed
post-doctoral training in the United States. Dr. Chen has held numerous
leadership positions in professional scientific trade organizations in China
as well as other parts of the world.
"On behalf of our entire organization, we are eager to collaborate with
such a high-quality preclinical CRO as MPI Research," says Shanghai Medicilon
CEO, Dr. Chen. "Both companies are committed to learning from each other. As
we incorporate the scientific expertise, high GLP standards and broad range of
services offered by MPI Research, we also look forward to sharing our
A multidisciplinary team of experts originating from MPI Research
headquarters will relocate to Shanghai and form a GLP Advisory Board to
oversee the US FDA GLP compliance process. This team has a broad range of
experience in areas such as small and large animal toxicology, safety
pharmacology, pharmacokinetics, animal care, quality assurance, report
writing, pathology, and study direction. In partnership with the MPI Research
team, over 70 Shanghai Medicilon professionals will be joining the newly
Headquartered in Michigan, USA, MPI Research has over 1600 people that
provide a comprehensive range of preclinical drug discovery and development
research. Known for its quality and timeliness, the company serves the
pharmaceutical and biotechnology industries in advancing their drug
development programs, from early proof of concept testing to regulatory
Shanghai Medicilon was founded in 2004 to provide fully integrated drug
discovery services to the pharmaceutical and biotechnology industries.
Medicilon has been recognized as one of the top drug discovery CROs in China.
Located in Shanghai at the Zhangjiang Hi-Tech Park, Medicilon's 250+ employees
provide integrated drug discovery and development services, incorporating
medicinal chemistry, lead optimization, custom chemical synthesis, biology
services pharmacokinetics, metabolism, and other key services such as, animal
toxicology, efficacy and disease model studies.
MPI Research and Medicilon will remain as independent parent companies to
the newly formed joint venture. For further information on each, visit their
respective websites at www.mpiresearch.com & www.medicilon.com.
For further information:
For further information: MPI Research William Harrison, 269-668-3336
William.Harrison@mpiresearch.com or Shanghai Medicilon Chun-Lin Chen, PhD,